Table 2.

Patient demographic and clinical characteristics for core cohort, no-ESRD, and ESRD groups

Characteristic n (%)All Patients 95 (100%)No-ESRD 67 (71%)ESRD 28 (29%)No-ESRD versus ESRD P Value
Gender0.79
    female76 (80%)54 (81%)22 (79%)
    male19 (20%)13 (19%)6 (21%)
Race
    African American53 (56%)32 (48%)21 (75%)<0.03
    Hispanic28 (29%)24 (36%)4 (14%)<0.05
    Caucasian10 (11%)9 (13%)1 (4%)0.27
    Asian4 (4%)2 (3%)2 (7%)0.58
SES0.99
    median household income $ × 103$35.4 ± 13.0$36.0 ± 14.3$34.0 ± 10.0
SES >10% poverty by zip code66 (75%)44 (72%)23 (82%)0.14
WHO class
    III9 (10%)8 (12%)1 (4%)0.27
    IV69 (73%)46 (70%)23 (82%)0.30
    V16 (17%)12 (18%)4 (14%)0.77
Age of onset (years)12.3 ± 2.912.9 ± 2.711.9 ± 3.10.12
Median time to progression: stage 3 CKD or higher8.0 (0.2 to 10.0)Undefined (2.5 to 8.0)3.2 (0.2 to 10.0)<0.01
Mean follow-up (years)6.0 ± 4.05.1 ± 3.67.7 ± 4.2<0.01
Initial eGFR (ml/min per 1.73 m2)107 ± 49117 ± 4983 ± 41<0.01
Final eGFR (ml/min per 1.73 m2)87 ± 60117 ± 4212 ± 5<0.01
Initial UPr/Cr (mg/mg)2.7 ± 2.62.6 ± 2.82.9 ± 2.10.61
Final UPr/Cr (mg/mg)2.5 ± 4.91.3 ± 2.37.5 ± 8.2<0.01
  • SES, socioeconomic status; eGFR, estimated GFR in ml/min per 1.73 m2; CKD, chronic kidney disease; UPr/Cr, urine protein-to-creatinine ratio (normal < 0.2).